Drugs Losing Exclusivity
Molecule-level cliff timing.
A defensible view of drugs losing market exclusivity 2026–2030 — molecule-level timing, geographic variance, and revenue erosion forecasts.
"Which specific molecules will lose exclusivity in our defense / attack window?"
A molecule-level exclusivity calendar with PoS-on-erosion modeling guides both defender lifecycle and biosimilar / generic entry strategy.
The 2026–2030 exclusivity-loss window is dense. Molecule-level resolution with country-specific erosion forecasts is the only credible basis for defender or challenger strategy.
What we’re seeing in the data.
Molecule-level resolution required
TA-level views miss 30%+ of opportunity.
Erosion curves vary by molecule
Biosimilar uptake 3× faster in some markets.
Authorized generics shape erosion
Defender lever.
How to think about it.
-
01
Build molecule calendar
Country-by-country.
-
02
Forecast erosion curves
Historical biosimilar / generic uptake.
-
03
Model defender plays
AG, lifecycle, formulation.
-
04
Map challenger entry
Manufacturing, regulatory, channel.
What separates a good answer from a defensible one.
Can extend or compress.
Reference pricing chains.
Affects switch dynamics.
Where the signal comes from.
Common questions.
How granular?
Molecule × country × indication.
Defender ROI?
Lifecycle and AG plays typically retain 40–70% of pre-cliff revenue.
Want this answered on your data?
We build decision systems on top of analyses like this — so the next question takes minutes, not weeks.
Talk to a strategist